Pharmacy Times® interviewed Petros Grivas, MD, PhD, associate professor at the University of Washington and Fred Hutchinson Cancer Research Center and a medical oncologist at Seattle Cancer Care Alliance, on the work of the COVID-19 and Cancer Consortium.
Patients recently diagnosed with cancer are significantly more likely to quit smoking and remain tobacco-free if they receive frequent phone counseling over an extended period of time.
A new breast cancer combination treatment may help patients with certain gene mutations, according to a study published in Molecular Cell.
A new device that delivers doses in tenths of a second rather than minutes may bypass adverse effects associated with traditional cancer radiation therapy.
Black women experience longer waiting periods before treatment is initiated than White women following a breast cancer diagnosis, as well as a prolonged treatment duration compared with White women.
Angiotensin receptor II blockers are often prescribed to control hypertension or for heart failure, kidney failure, or following a heart attack.
The United States Preventive Services Task Force updates recommends that colorectal cancer screening begin 5 years earlier, at age 45 instead of age 50.
Study to evaluate paclitaxel plus encequidar with dostarlimab +/- carboplatin in patients with breast cancer.
Data show that children with cancer who are experiencing neighborhood poverty and rely on public health insurance have an increased risk of death with stem cell treatment.
FDA lift clinical hold placed on the phase 1 PSMA-101-001 study of the chimeric antigen receptor T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.
FDA approves the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR TKIs in the treatment of EGFR-mutated non–small cell lung cancer.
The FDA granted priority review to a supplemental biologics license application for cemiplimab-rwlc for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer.
Approximately 30% of women gain weight following chemotherapy for breast cancer, gut bacteria may be why.
The FDA granted priority review to a supplemental biologics license application for trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma.
FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.
An axillary lymph node dissection, which is the surgical removal of 10 to 20 lymph nodes from the breast, is a procedure conducted in up to 25% of women with breast cancer to disable symptoms of arm swelling.
Lipid-lowering medication may be an effective adjuvant cancer therapy.
The FDA has approved the FoundationOne CDx (F1CDx) comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions across all solid tumors.
Cholesterol-lowering statins have been found to potentially reduce the risk of cancer via a pathway that is unrelated to its impact on cholesterol, according to a recent study.
The specialty pipeline continues to grow at a rapid pace with a number of FDA approvals in 2019 for either new therapies or first in class for certain conditions, and many more drugs in development.
Patients with current or former smoking status may be at an increased risk of severe illness due to COVID-19.
The FDA granted osimertinib (Tagrisso) priority review designation for the adjuvant treatment of patients with early-stage EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.
oNKord is a natural killer cellular immunotherapy product, meaning it can play an important role in controlling and curing both solid and hematological malignancies.
Pembrolizumab (Keytruda) has demonstrated promising activity when used in combination with chemotherapy or quavonlimab in select patients with nonsquamous non–small cell lung cancer.
The Mary Pazdur Award was presented during the JADPRO Live Virtual conference.
Pharmacy Times® interviewed Petros Grivas, associate professor at the University of Washington and Fred Hutchinson Cancer Research Center and a medical oncologist at Seattle Cancer Care Alliance, on the value of the pharmacist in the treatment of patients with cancer during COVID-19.
Top news of the week from Pharmacy Times.
Women diagnosed with cancer as adolescents or young adults can be especially vulnerable to the impact of the disease and its treatment on their ability to work.
Despite it being fall, sun safety is important all year and even needs to be considered for winter sport activities, such as snowboarding and skiing.
Evidence-based cancer regimens have been shown to result in better outcomes, including longer survival and less toxicity.
